Skip to main content

Table 2 Baseline characteristics by HIV status

From: Recurrence of cervical intraepithelial lesions after thermo-coagulation in HIV-positive and HIV-negative Nigerian women

Characteristics

 

HIV-positive (N = 120) n (%)

HIV-negative (N = 57) n (%)

P value*

Age

  < 30 years

n (%)

34.0 (28.3)

11.0 (19.3)

0.27

  ≥ 30 years

n (%)

86.0 (71.7)

46.0 (80.7)

Age at first intercourse

  < 18 years

n (%)

36.0 (30.2)

10.0 (18.2)

0.10

  ≥ 18 years

n (%)

83.0 (69.8)

45.0 (81.8)

Number of Sexual Partners

  ≤ 1

n (%)

97.0 (82.2)

48.0 (85.7)

0.67

  > 1

n (%)

21.0 (17.8)

8.0 (14.3)

Elective Abortions

 Ever

n (%)

89.0 (76.7)

28.0 (56.0)

0.01*

 Never

n (%)

27.0 (23.3)

22.0 (44.0)

Number of Pregnancies

  < 5

n (%)

84.0 (70.6)

30.0 (53.6)

0.04*

  ≥ 5

n (%)

35.0 (29.4)

26.0 (46.4)

Miscarriages

 Ever

n (%)

9.0 (8.3)

11.0 (21.6)

0.04*

 Never

n (%)

99.0 (91.7)

40.0 (78.4)

Body Mass Index (BMI), Mean (SD)

 

24.4 (5.2)

28.9 (6.5)

0.02*

Marital Status

 Ever Married

n (%)

88.0 (73.3)

47.0 (82.5)

0.26

 Never Married

n (%)

32.0 (26.7)

10.0 (17.5)

Highest Education

 Post-secondary

n (%)

52.0 (43.7)

36.0 (63.2)

0.02*

  ≤ Secondary

n (%)

67.0 (56.3)

21.0 (36.8)

Contraceptive use

 Ever

n (%)

51.0 (42.5)

35.0 (61.4)

0.02*

 Never

n (%)

69.0 (57.5)

22.0 (38.6)

Genital Lesions (Warts, Sores or Ulcers)

 Yes

n (%)

9 (40.9)

5 (14.7)

0.06

 No

n (%)

13 (59.1)

29 (85.3)

Follow up duration in days, Median (Interquartile Range)a

 

793.5 (758.0)

371.0 (274.0)

<.0001*

Losses to follow-up

n (%)

47.0 (28.1)

38.0 (40.0)

0.06

CD4 Count (cells/mm3)

  < 200

n (%)

22.0 (23.7)

--

 

  ≥ 200

n (%)

71.0 (76.3)

HAART use

 Yes

n (%)

105.0 (87.5 %)

--

 

 No

n (%)

15.0 (12.5 %)

HAART REGIMEN

 AZT-3TC-NVP

n (%)

49 (53.26)

--

 

 EFV-TDF-3TC

n (%)

18 (19.57)

 NVP-TDF-3TC

n (%)

7 (7.61)

 AZT-3TC-EFV

n (%)

4 (4.35)

 LPV/r-TDF-3TC

n (%)

4 (4.35)

 TDF-FTC-EFV

n (%)

4 (4.35)

 AZT-3TC-LPV/r

n (%)

2 (2.17)

 D4T-3TC-NVP

n (%)

2 (2.17)

 TDF-FTC-NVP

n (%)

2 (2.17)

  1. AZT Zidovudine, 3TC Lamivudine, NVP Nevirapine, EFV Efavirenz, TDF Tenofovir, LPV/r Lopinavir/Ritonavir, FTC Emtricitabine, D4T Stavudine
  2. *Statistically significant at 0.05 level
  3. aComparison of medians was done using Wilcoxon rank-sum test